AU2008226291B2 - Reoviruses having modified sequences - Google Patents

Reoviruses having modified sequences Download PDF

Info

Publication number
AU2008226291B2
AU2008226291B2 AU2008226291A AU2008226291A AU2008226291B2 AU 2008226291 B2 AU2008226291 B2 AU 2008226291B2 AU 2008226291 A AU2008226291 A AU 2008226291A AU 2008226291 A AU2008226291 A AU 2008226291A AU 2008226291 B2 AU2008226291 B2 AU 2008226291B2
Authority
AU
Australia
Prior art keywords
reovirus
seq
nucleic acid
residue
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008226291A
Other languages
English (en)
Other versions
AU2008226291A2 (en
AU2008226291A1 (en
Inventor
Matthew C. Coffey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncolytics Biotech Inc
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39758956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008226291(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of AU2008226291A1 publication Critical patent/AU2008226291A1/en
Publication of AU2008226291A2 publication Critical patent/AU2008226291A2/en
Priority to AU2013201835A priority Critical patent/AU2013201835A1/en
Application granted granted Critical
Publication of AU2008226291B2 publication Critical patent/AU2008226291B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2008226291A 2007-03-12 2008-03-14 Reoviruses having modified sequences Active AU2008226291B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013201835A AU2013201835A1 (en) 2007-03-12 2013-03-22 Reoviruses having modified sequences

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89442507P 2007-03-12 2007-03-12
US60/894,425 2007-03-12
US98956807P 2007-11-21 2007-11-21
US60/989,568 2007-11-21
PCT/CA2008/000483 WO2008110004A1 (en) 2007-03-12 2008-03-11 Reoviruses having modified sequences

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013201835A Division AU2013201835A1 (en) 2007-03-12 2013-03-22 Reoviruses having modified sequences

Publications (3)

Publication Number Publication Date
AU2008226291A1 AU2008226291A1 (en) 2008-09-18
AU2008226291A2 AU2008226291A2 (en) 2009-10-08
AU2008226291B2 true AU2008226291B2 (en) 2014-01-16

Family

ID=39758956

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008226291A Active AU2008226291B2 (en) 2007-03-12 2008-03-14 Reoviruses having modified sequences

Country Status (16)

Country Link
US (5) US7803385B2 (https=)
EP (2) EP2952583A1 (https=)
JP (1) JP5577103B2 (https=)
KR (1) KR101647843B1 (https=)
CN (1) CN103710359A (https=)
AR (1) AR066395A1 (https=)
AU (1) AU2008226291B2 (https=)
CA (1) CA2678721C (https=)
DK (1) DK2132315T3 (https=)
ES (1) ES2548442T3 (https=)
IL (4) IL200353A (https=)
MX (2) MX2009009598A (https=)
SG (1) SG191602A1 (https=)
TW (1) TW200904979A (https=)
WO (1) WO2008110004A1 (https=)
ZA (1) ZA200905951B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
JP5577103B2 (ja) 2007-03-12 2014-08-20 オンコリティクス バイオテク，インコーポレーテッド 改変配列を有するレオウイルス
EP2211880A4 (en) * 2007-10-22 2012-11-14 Oncolytics Biotech Inc TREATMENT PROCEDURE FOR PROLIFERATIVE DISEASES
MX339014B (es) * 2008-05-27 2016-05-09 Oncolytics Biotech Inc Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
WO2009158618A2 (en) * 2008-06-26 2009-12-30 Biomune Company Unique avian reoviridae
FR2939807B1 (fr) * 2008-12-11 2010-12-17 Biomerieux Sa Nouveau reovirus isole, procedes et kits de detection
EP2482824B1 (en) 2009-10-02 2016-11-30 The Trustees of Columbia University in the City of New York Piscine reovirus immunogenic compositions
MX349294B (es) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
AU2011336413B2 (en) * 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
JP6029651B2 (ja) * 2011-04-29 2016-11-24 オンコリティクス バイオテク，インコーポレーテッド ゲル浸透クロマトグラフィーを使用してウイルスを精製する方法
WO2015070323A1 (en) 2013-11-15 2015-05-21 Oncolytics Biotech Inc. Oncolytic viruses and increased cancer treatment regimens
US9660989B1 (en) 2014-01-31 2017-05-23 Google Inc. Internet-wide identity management widget
JP6875745B2 (ja) 2016-02-16 2021-05-26 国立大学法人大阪大学 線維化を治療するための医薬組成物
WO2019237063A1 (en) * 2018-06-07 2019-12-12 Emory University Modified reoviruses, particles, and uses in treating proliferative disorders
KR102401077B1 (ko) 2019-01-25 2022-05-24 바이로큐어 주식회사 다람쥐 섬유종 바이러스 및 리오바이러스를 포함하는 암 예방 또는 치료용 약학적 조성물
WO2020227245A1 (en) * 2019-05-03 2020-11-12 Kansas State University Research Foundation Immunogenic compositions for novel reassortant mammalian ortheovirus from pigs
CN116917468A (zh) * 2020-12-22 2023-10-20 百洛克株式会社 新型修饰的呼肠孤病毒及其用途
WO2022139490A1 (ko) * 2020-12-22 2022-06-30 바이로큐어 주식회사 신규한 변형 레오바이러스 및 이의 용도
US20250154204A1 (en) * 2021-09-24 2025-05-15 Virocure, Inc. Novel reovirus-based vaccine platform and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US20060165724A1 (en) * 2000-08-10 2006-07-27 Oncolytics Biotech Inc. Method of producing infectious reovirus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
BR0115235A (pt) 2000-11-09 2003-10-14 Oncolytics Biotech Inc Métodos de determinar a suscetibilidade de uma célula à infecção por reovìrus, e, uso de uma composição compreendendo um ou mais reovìrus
JP2004519431A (ja) * 2000-12-01 2004-07-02 ユニバーシティ・オブ・オタワ 腫瘍溶解性ウイルス
DK2253701T3 (da) 2001-03-16 2014-10-20 Oncolytics Biotech Inc Fremgangsmåde til ekstraktion af en virus fra en cellekultur
US7163678B2 (en) 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
WO2006001120A1 (ja) 2004-06-24 2006-01-05 Dnavec Research Inc. マイナス鎖rnaウイルスを含む抗癌剤
WO2007099401A2 (en) * 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
US20100086522A1 (en) 2006-07-18 2010-04-08 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
JP5577103B2 (ja) 2007-03-12 2014-08-20 オンコリティクス バイオテク，インコーポレーテッド 改変配列を有するレオウイルス
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
AU2011336413B2 (en) * 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
MX349294B (es) * 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US20060165724A1 (en) * 2000-08-10 2006-07-27 Oncolytics Biotech Inc. Method of producing infectious reovirus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [Online] 1 August 1990, Accession no. P:17376 *
DATABASE UniProt [Online] 31 October 2006, Accession no. Q06BD2 *
DERMODY, T.S. et al. Journal of Virology, 1991, Vol. 65, pages 5721-5731 *
MCCUTCHEON, A.M. et al. Virology, 1999. Vol. 264, pages 16-24 *
WIENER J.R. et al, Virology, 1989, Vol. 169, pages 194-203 *

Also Published As

Publication number Publication date
JP5577103B2 (ja) 2014-08-20
IL221702A0 (en) 2012-10-31
US10596260B2 (en) 2020-03-24
DK2132315T3 (en) 2015-10-19
US20140186301A1 (en) 2014-07-03
US11246930B2 (en) 2022-02-15
IL221700A0 (en) 2012-10-31
AR066395A1 (es) 2009-08-19
ZA200905951B (en) 2010-11-24
AU2008226291A2 (en) 2009-10-08
KR20090125103A (ko) 2009-12-03
AU2008226291A1 (en) 2008-09-18
WO2008110004A1 (en) 2008-09-18
US8691241B2 (en) 2014-04-08
EP2952583A1 (en) 2015-12-09
EP2132315B1 (en) 2015-07-15
HK1132761A1 (en) 2010-03-05
SG191602A1 (en) 2013-07-31
CA2678721C (en) 2018-02-13
EP2132315A1 (en) 2009-12-16
ES2548442T3 (es) 2015-10-16
IL221701A0 (en) 2012-10-31
US20090035278A2 (en) 2009-02-05
IL200353A (en) 2017-07-31
JP2010520758A (ja) 2010-06-17
US20110020288A1 (en) 2011-01-27
US20080226602A1 (en) 2008-09-18
TW200904979A (en) 2009-02-01
MX346950B (es) 2017-04-06
MX2009009598A (es) 2009-09-21
CN103710359A (zh) 2014-04-09
EP2132315A4 (en) 2011-10-05
CA2678721A1 (en) 2008-09-18
US10039827B2 (en) 2018-08-07
US20200237917A1 (en) 2020-07-30
US7803385B2 (en) 2010-09-28
KR101647843B1 (ko) 2016-08-11
US20180344853A1 (en) 2018-12-06
IL200353A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
US11246930B2 (en) Reoviruses having modified sequences
AU2008253505B2 (en) Mutant reoviruses and methods of making and using
AU2001275628A1 (en) Method of producing infectious reovirus
EP1309672A1 (en) Method of producing infectious reovirus
TW200951143A (en) Modulating interstitial pressure and oncolytic viral delivery and distribution
AU2009253683B2 (en) Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
AU2013201835A1 (en) Reoviruses having modified sequences
HK1132761B (en) Reoviruses having modified sequences
CN101627122A (zh) 具有修饰的序列的呼肠孤病毒
HK1136006B (en) Mutant reoviruses and methods of making and using

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 SEP 2009

FGA Letters patent sealed or granted (standard patent)